Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma - Top-Institutions - MDSpire

Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma

  • By

  • Zhumei Zhan

  • Peipei Li

  • Yanlu Liu

  • Changqing Zhen

  • Ying Zhang

  • Ou Bai

  • May 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology Oncology
    • Cancer Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology Oncology
    • Cancer Research

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hematology Oncology
    • Transplantation

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Hematology Oncology
    • Cancer Research

  • #5

    City of Hope
    City of Hope

    Duarte, California

    Key Differentiators

    • Hematology Oncology
    • Transplantation

Original Source(s)

Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma

  • by Zhumei Zhan, Peipei Li, Yanlu Liu, Changqing Zhen, Ying Zhang, Ou Bai

  • May 8, 2026

Related Content

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort